Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2009

View Archived Issues

Novel Rho kinase inhibitors in early development at Abbott

Merck KGaA claims sodium-glucose transporter inhibitors as antidiabetics

Johns Hopkins University describes novel protease inhibitors for treating HCV infection

HDAC1 inhibitors presented by Novartis for the treatment of cancer

Novel Plk-1 inhibitors identified by 4SC for the treatment of cancer

Abbott claims novel GlyT-1 inhibitors as anxiolytics

UAB, Southern Research and Jubilant Organosys enter joint venture

Cytokinetics discloses preclinical data on novel smooth muscle myosin inhibitors

Antimalaria vaccine elicits functional antibodies in phase I trial in malaria-naive subjects

ICOVIR-17 adenovirus displays enhanced intratumoral distribution and activity in vivo

GW-876008 improves stress-induced rectal hypersensitivity in patients with IBS

Preclinical characterization of RP-1040 disclosed at 2009 AACR-NCI-EORTC meeting

Novartis ends asthma and allergy research agreement with Idera Pharmaceuticals

Multaq approved in E.U. for treatment of atrial fibrillation

ATIR enters advanced clinical testing for graft-versus-host disease

Studies clarify genetic predisposition for Chlamydia trachomatis infections / News in Context

Complete response letter issued for extended indication of telavancin in the U.S.

European Commission approves Micardis for cardiovascular protection indication

EMEA validates ChemGenex's MAA for omacetaxine mepesuccinate

SciClone completes patient enrollment for SCV-07 phase II trial in oral mucositis

Roswell Park physician receives grant to investigate HDAC inhibitors in RCC

Photocure's NDA for Hexvix to be reviewed by FDA in December 2009

Approval of Pharmaxis' Aridol recommended by FDA advisory committee

MDRNA and Vancouver Prostate Center to extend collaboration on bladder cancer project

Encouraging phase II data on K-201 in atopic eczema announced by Moberg Derma

GlaxoSmithKline withdraws U.S. supplemental NDA for Avodart

GlaxoSmithKline discloses promising clinical data on H1N1 vaccine Pandemrix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...